Pune: In a landmark development for women’s health, Mylab Discovery Solutions has launched India’s first indigenously developed High-Risk HPV DNA RT-PCR kit for cervical cancer screening. The PathoDetect HPV DNA Kit, validated through a multicentric trial under the GCI-BIRAC-DBT initiative, was unveiled by Union Minister Dr. Jitendra Singh, marking a pivotal step toward the elimination of cervical cancer in India.
Tailored for Mylab’s fully automated Compact platform, the kit delivers rapid, reliable, and high-throughput cervical cancer diagnostics. The cartridge-based solution simplifies operations by eliminating the need for pipettes, enabling contamination-free, walkaway testing that’s especially suitable for rural and underserved healthcare settings.
“Mylab’s innovation aligns with India’s mission to democratize healthcare by making advanced diagnostics accessible, affordable, and efficient,” said Hasmukh Rawal, Managing Director and Co-Founder, MyLab Discovery Solutions. “This is not just a test—it’s a tool to empower early detection and promote self-reliance in healthcare.”
Key features of the Mylab PathoDetect™ High-Risk HPV Kit:
- Molecular-based RT-PCR method for high accuracy
- Widest coverage of high-risk HPV strains
- Room temperature reagent stability
- Intuitive software for tracking, reporting, and tracing
- Flexible sample collection using cervical swabs or first-void urine
The launch comes at a time when India is prioritizing preventive healthcare for women. With cervical cancer being the second-most common cancer among Indian women, early screening remains critical. Mylab’s kit addresses this gap by offering an affordable, high-throughput solution compatible with decentralized healthcare systems.
Mylab Discovery Solutions
Backed by government endorsements and scientific validation, Mylab Discovery Solutions continues to lead India’s diagnostics innovation movement. The launch of the HPV DNA kit further cements its position as a pioneer in automated, molecular diagnostics.
